- •Contents
- •Contributors
- •Part I General Principles of Cell Death
- •1 Human Caspases – Apoptosis and Inflammation Signaling Proteases
- •1.1. Apoptosis and limited proteolysis
- •1.2. Caspase evolution
- •2. ACTIVATION MECHANISMS
- •2.2. The activation platforms
- •2.4. Proteolytic maturation
- •3. CASPASE SUBSTRATES
- •4. REGULATION BY NATURAL INHIBITORS
- •REFERENCES
- •2 Inhibitor of Apoptosis Proteins
- •2. CELLULAR FUNCTIONS AND PHENOTYPES OF IAP
- •3. IN VIVO FUNCTIONS OF IAP FAMILY PROTEINS
- •4. SUBCELLULAR LOCATIONS OF IAP
- •8. IAP–IAP INTERACTIONS
- •10. ENDOGENOUS ANTAGONISTS OF IAP
- •11. IAPs AND DISEASE
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2.1. The CD95 (Fas/APO-1) system
- •2.1.1. CD95 and CD95L: discovery of the first direct apoptosis-inducing receptor-ligand system
- •2.1.2. Biochemistry of CD95 apoptosis signaling
- •2.2. The TRAIL (Apo2L) system
- •3.1. The TNF system
- •3.1.1. Biochemistry of TNF signal transduction
- •3.1.2. TNF and TNF blockers in the clinic
- •3.2. The DR3 system
- •4. THE DR6 SYSTEM
- •6. CONCLUDING REMARKS AND OUTLOOK
- •SUGGESTED READINGS
- •4 Mitochondria and Cell Death
- •1. INTRODUCTION
- •2. MITOCHONDRIAL PHYSIOLOGY
- •3. THE MITOCHONDRIAL PATHWAY OF APOPTOSIS
- •9. CONCLUSIONS
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •3. INHIBITING APOPTOSIS
- •4. INHIBITING THE INHIBITORS
- •6. THE BCL-2 FAMILY AND CANCER
- •SUGGESTED READINGS
- •6 Endoplasmic Reticulum Stress Response in Cell Death and Cell Survival
- •1. INTRODUCTION
- •2. THE ESR IN YEAST
- •3. THE ESR IN MAMMALS
- •4. THE ESR AND CELL DEATH
- •5. THE ESR IN DEVELOPMENT AND TISSUE HOMEOSTASIS
- •6. THE ESR IN HUMAN DISEASE
- •7. CONCLUSION
- •7 Autophagy – The Liaison between the Lysosomal System and Cell Death
- •1. INTRODUCTION
- •2. AUTOPHAGY
- •2.2. Physiologic functions of autophagy
- •2.3. Autophagy and human pathology
- •3. AUTOPHAGY AND CELL DEATH
- •3.1. Autophagy as anti–cell death mechanism
- •3.2. Autophagy as a cell death mechanism
- •3.3. Molecular players of the autophagy–cell death cross-talk
- •4. AUTOPHAGY, CELLULAR DEATH, AND CANCER
- •5. CONCLUDING REMARKS AND PENDING QUESTIONS
- •SUGGESTED READINGS
- •8 Cell Death in Response to Genotoxic Stress and DNA Damage
- •1. TYPES OF DNA DAMAGE AND REPAIR SYSTEMS
- •2. DNA DAMAGE RESPONSE
- •2.2. Transducers
- •2.3. Effectors
- •4. CHROMATIN MODIFICATIONS
- •5. CELL CYCLE CHECKPOINT REGULATION
- •6. WHEN REPAIR FAILS: SENESCENCE VERSUS APOPTOSIS
- •6.1. DNA damage response and the induction of apoptosis
- •6.2. p53-independent mechanisms of apoptosis
- •6.3. DNA damage response and senescence induction
- •7. DNA DAMAGE FROM OXIDATIVE STRESS
- •SUGGESTED READINGS
- •9 Ceramide and Lipid Mediators in Apoptosis
- •1. INTRODUCTION
- •3.1. Basic cell signaling often involves small molecules
- •3.2. Sphingolipids are cell-signaling molecules
- •3.2.1. Ceramide induces apoptosis
- •3.2.2. Ceramide accumulates during programmed cell death
- •3.2.3. Inhibition of ceramide production alters cell death signaling
- •4.1. Ceramide is generated through SM hydrolysis
- •4.3. aSMase can be activated independently of extracellular receptors to regulate apoptosis
- •4.4. Controversial aspects of the role of aSMase in apoptosis
- •4.5. De novo ceramide synthesis regulates programmed cell death
- •4.6. p53 and Bcl-2–like proteins are connected to de novo ceramide synthesis
- •4.7. The role and regulation of de novo synthesis in ceramide-mediated cell death is poorly understood
- •5. CONCLUDING REMARKS AND FUTURE DIRECTIONS
- •5.1. Who? (Which enzyme?)
- •5.2. What? (Which ceramide?)
- •5.3. Where? (Which compartment?)
- •5.4. When? (At what steps?)
- •5.5. How? (Through what mechanisms?)
- •5.6. What purpose?
- •6. SUMMARY
- •SUGGESTED READINGS
- •1. General Introduction
- •1.1. Cytotoxic lymphocytes and apoptosis
- •2. CYTOTOXIC GRANULES AND GRANULE EXOCYTOSIS
- •2.1. Synthesis and loading of the cytotoxic granule proteins into the secretory granules
- •2.2. The immunological synapse
- •2.3. Secretion of granule proteins
- •2.4. Uptake of proapoptotic proteins into the target cell
- •2.5. Activation of death pathways by granzymes
- •3. GRANULE-BOUND CYTOTOXIC PROTEINS
- •3.1. Perforin
- •3.2. Granulysin
- •3.3. Granzymes
- •3.3.1. GrB-mediated apoptosis
- •3.3.2. GrA-mediated cell death
- •3.3.3. Orphan granzyme-mediated cell death
- •5. CONCLUSIONS
- •REFERENCES
- •Part II Cell Death in Tissues and Organs
- •1.1. Death by trophic factor deprivation
- •1.2. Key molecules regulating neuronal apoptosis during development
- •1.2.1. Roles of caspases and Apaf-1 in neuronal cell death
- •1.2.2. Role of Bcl-2 family members in neuronal cell death
- •1.3. Signal transduction from neurotrophins and neurotrophin receptors
- •1.3.1. Signals for survival
- •1.3.2. Signals for death
- •2.1. Apoptosis in neurodegenerative diseases
- •2.1.4. Amyotrophic lateral sclerosis
- •2.2. Necrotic cell death in neurodegenerative diseases
- •2.2.1. Calpains
- •2.2.2. Cathepsins
- •3. CONCLUSIONS
- •ACKNOWLEDGMENT
- •SUGGESTED READINGS
- •ACKNOWLEDGMENT
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •5. S-NITROSYLATION OF PARKIN
- •7. POTENTIAL TREATMENT OF EXCESSIVE NMDA-INDUCED Ca2+ INFLUX AND FREE RADICAL GENERATION
- •8. FUTURE THERAPEUTICS: NITROMEMANTINES
- •9. CONCLUSIONS
- •Acknowledgments
- •SUGGESTED READINGS
- •3. MITOCHONDRIAL PERMEABILITY TRANSITION ACTIVATED BY Ca2+ AND OXIDATIVE STRESS
- •4.1. Mitochondrial apoptotic pathways
- •4.2. Bcl-2 family proteins
- •4.3. Caspase-dependent apoptosis
- •4.4. Caspase-independent apoptosis
- •4.5. Calpains in ischemic neural cell death
- •5. SUMMARY
- •ACKNOWLEDGMENTS
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2. HISTORICAL ANTECEDENTS
- •7.1. Activation of p21 waf1/cip1: Targeting extrinsic and intrinsic pathways to death
- •8. CONCLUSION
- •ACKNOWLEDGMENTS
- •REFERENCES
- •16 Apoptosis and Homeostasis in the Eye
- •1.1. Lens
- •1.2. Retina
- •2. ROLE OF APOPTOSIS IN DISEASES OF THE EYE
- •2.1. Glaucoma
- •2.2. Age-related macular degeneration
- •4. APOPTOSIS AND OCULAR IMMUNE PRIVILEGE
- •5. CONCLUSIONS
- •SUGGESTED READINGS
- •17 Cell Death in the Inner Ear
- •3. THE COCHLEA IS THE HEARING ORGAN
- •3.1. Ototoxic hair cell death
- •3.2. Aminoglycoside-induced hair cell death
- •3.3. Cisplatin-induced hair cell death
- •3.4. Therapeutic strategies to prevent hair cell death
- •3.5. Challenges to studies of hair cell death
- •4. SPIRAL GANGLION NEURON DEATH
- •4.1. Neurotrophic support from sensory hair cells and supporting cells
- •4.2. Afferent activity from hair cells
- •4.3. Molecular manifestations of spiral ganglion neuron death
- •4.4. Therapeutic interventions to prevent SGN death
- •ACKNOWLEDGMENTS
- •SUGGESTED READINGS
- •18 Cell Death in the Olfactory System
- •1. Introduction
- •2. Anatomical Aspects
- •3. Life and Death in the Olfactory System
- •3.1. Olfactory epithelium
- •3.2. Olfactory bulb
- •REFERENCES
- •1. Introduction
- •3.1. Beta cell death in the development of T1D
- •3.2. Mechanisms of beta cell death in type 1 diabetes
- •3.2.1. Apoptosis signaling pathways downstream of death receptors and inflammatory cytokines
- •3.2.2. Oxidative stress
- •3.3. Mechanisms of beta cell death in type 2 diabetes
- •3.3.1. Glucolipitoxicity
- •3.3.2. Endoplasmic reticulum stress
- •5. SUMMARY
- •Acknowledgments
- •REFERENCES
- •20 Apoptosis in the Physiology and Diseases of the Respiratory Tract
- •1. APOPTOSIS IN LUNG DEVELOPMENT
- •2. APOPTOSIS IN LUNG PATHOPHYSIOLOGY
- •2.1. Apoptosis in pulmonary inflammation
- •2.2. Apoptosis in acute lung injury
- •2.3. Apoptosis in chronic obstructive pulmonary disease
- •2.4. Apoptosis in interstitial lung diseases
- •2.5. Apoptosis in pulmonary arterial hypertension
- •2.6. Apoptosis in lung cancer
- •SUGGESTED READINGS
- •21 Regulation of Cell Death in the Gastrointestinal Tract
- •1. INTRODUCTION
- •2. ESOPHAGUS
- •3. STOMACH
- •4. SMALL AND LARGE INTESTINE
- •5. LIVER
- •6. PANCREAS
- •7. SUMMARY AND CONCLUDING REMARKS
- •SUGGESTED READINGS
- •22 Apoptosis in the Kidney
- •1. NORMAL KIDNEY STRUCTURE AND FUNCTION
- •3. APOPTOSIS IN ADULT KIDNEY DISEASE
- •4. REGULATION OF APOPTOSIS IN KIDNEY CELLS
- •4.1. Survival factors
- •4.2. Lethal factors
- •4.2.1. TNF superfamily cytokines
- •4.2.2. Other cytokines
- •4.2.3. Glucose
- •4.2.4. Drugs and xenobiotics
- •4.2.5. Ischemia-reperfusion and sepsis
- •5. THERAPEUTIC APPROACHES
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2. APOPTOSIS IN THE NORMAL BREAST
- •2.1. Occurrence and role of apoptosis in the developing breast
- •2.2.2. Death ligands and death receptor pathway
- •2.2.4. LIF-STAT3 proapoptotic signaling
- •2.2.5. IGF survival signaling
- •2.2.6. Regulation by adhesion
- •2.2.7. PI3K/AKT pathway: molecular hub for survival signals
- •2.2.8. Downstream regulators of apoptosis: the BCL-2 family members
- •3. APOPTOSIS IN BREAST CANCER
- •3.1. Apoptosis in breast tumorigenesis and cancer progression
- •3.2. Molecular dysregulation of apoptosis in breast cancer
- •3.2.1. Altered expression of death ligands and their receptors in breast cancer
- •3.2.2. Deregulation of prosurvival growth factors and their receptors
- •3.2.3. Alterations in cell adhesion and resistance to anoikis
- •3.2.4. Enhanced activation of the PI3K/AKT pathway in breast cancer
- •3.2.5. p53 inactivation in breast cancer
- •3.2.6. Altered expression of BCL-2 family of proteins in breast cancer
- •5. CONCLUSION
- •SUGGESTED READINGS
- •1. INTRODUCTION
- •2. DETECTING CELL DEATH IN THE FEMALE GONADS
- •4. APOPTOSIS AND FEMALE REPRODUCTIVE AGING
- •6. CONCLUDING REMARKS
- •REFERENCES
- •25 Apoptotic Signaling in Male Germ Cells
- •1. INTRODUCTION
- •3.1. Murine models
- •3.2. Primate models
- •3.3. Pathways of caspase activation and apoptosis
- •3.4. Apoptotic signaling in male germ cells
- •5. P38 MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) AND NITRIC OXIDE (NO)–MEDIATED INTRINSIC PATHWAY SIGNALING CONSTITUTES A CRITICAL COMPONENT OF APOPTOTIC SIGNALING IN MALE GERM CELLS AFTER HORMONE DEPRIVATION
- •11. CONCLUSIONS AND PERSPECTIVES
- •REFERENCES
- •26 Cell Death in the Cardiovascular System
- •1. INTRODUCTION
- •2. CELL DEATH IN THE VASCULATURE
- •2.1. Apoptosis in the developing blood vessels
- •2.2. Apoptosis in atherosclerosis
- •2.2.1. Vascular smooth muscle cells
- •2.2.2. Macrophages
- •2.2.3. Regulation of apoptosis in atherosclerosis
- •2.2.4. Necrosis and autophagy in atherosclerosis
- •3. CELL DEATH IN THE MYOCARDIUM
- •3.1. Cell death in myocardial infarction
- •3.1.1. Apoptosis in myocardial infarction
- •3.1.2. Necrosis in myocardial infarction
- •3.1.3. Autophagy in myocardial infarction
- •3.2. Cell death in heart failure
- •3.2.1. Apoptosis in heart failure
- •3.2.2. Necrosis in heart failure
- •3.2.3. Autophagy in heart failure
- •4. CONCLUDING REMARKS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •27 Cell Death Regulation in Muscle
- •1. INTRODUCTION TO MUSCLE
- •1.1. Skeletal muscle adaptation to endurance training
- •1.2. Myonuclear domains
- •2. MITOCHONDRIALLY MEDIATED APOPTOSIS IN MUSCLE
- •2.1. Skeletal muscle apoptotic susceptibility
- •4. APOPTOSIS IN MUSCLE DURING AGING AND DISEASE
- •4.1. Aging
- •4.2. Type 2 diabetes mellitus
- •4.3. Cancer cachexia
- •4.4. Chronic heart failure
- •6. CONCLUSION
- •SUGGESTED READINGS
- •28 Cell Death in the Skin
- •1. INTRODUCTION
- •2. CELL DEATH IN SKIN HOMEOSTASIS
- •2.1. Cornification and apoptosis
- •2.2. Death receptors in the skin
- •3. CELL DEATH IN SKIN PATHOLOGY
- •3.1. Sunburn
- •3.2. Skin cancer
- •3.3. Necrolysis
- •3.4. Pemphigus
- •3.5. Eczema
- •3.6. Graft-versus-host disease
- •4. CONCLUDING REMARKS AND PERSPECTIVES
- •ACKNOWLEDGMENTS
- •SUGGESTED READINGS
- •29 Apoptosis and Cell Survival in the Immune System
- •2.1. Survival of early hematopoietic progenitors
- •2.2. Sizing of the T-cell population
- •2.2.1. Establishing central tolerance
- •2.2.2. Peripheral tolerance
- •2.2.3. Memory T cells
- •2.3. Control of apoptosis in B-cell development
- •2.3.1. Early B-cell development
- •2.3.2. Deletion of autoreactive B cells
- •2.3.3. Survival and death of activated B cells
- •3. IMPAIRED APOPTOSIS AND LEUKEMOGENESIS
- •4. CONCLUSIONS
- •ACKNOWLEDGMENTS
- •REFERENCES
- •30 Cell Death Regulation in the Hematopoietic System
- •1. INTRODUCTION
- •2. HEMATOPOIETIC STEM CELLS
- •4. ERYTHROPOIESIS
- •5. MEGAKARYOPOIESIS
- •6. GRANULOPOIESIS
- •7. MONOPOIESIS
- •8. CONCLUSION
- •ACKNOWLEDGMENTS
- •REFERENCES
- •31 Apoptotic Cell Death in Sepsis
- •1. INTRODUCTION
- •2. HOST INFLAMMATORY RESPONSE TO SEPSIS
- •3. CLINICAL OBSERVATIONS OF CELL DEATH IN SEPSIS
- •3.1. Sepsis-induced apoptosis
- •3.2. Necrotic cell death in sepsis
- •4.1. Central role of apoptosis in sepsis mortality: immune effector cells and gut epithelium
- •4.2. Apoptotic pathways in sepsis-induced immune cell death
- •4.3. Investigations implicating the extrinsic apoptotic pathway in sepsis
- •4.4. Investigations implicating the intrinsic apoptotic pathway in sepsis
- •5. THE EFFECT OF APOPTOSIS ON THE IMMUNE SYSTEM
- •5.1. Cellular effects of an increased apoptotic burdens
- •5.2. Network effects of selective loss of immune cell types
- •5.3. Studies of immunomodulation by apoptotic cells in other fields
- •7. CONCLUSION
- •REFERENCES
- •32 Host–Pathogen Interactions
- •1. INTRODUCTION
- •2. FROM THE PATHOGEN PERSPECTIVE
- •2.1. Commensals versus pathogens
- •2.2. Pathogen strategies to infect the host
- •3. HOST DEFENSE
- •3.1. Antimicrobial peptides
- •3.2. PRRs and inflammation
- •3.2.1. TLRs
- •3.2.2. NLRs
- •3.2.3. The Nod signalosome
- •3.2.4. The inflammasome
- •3.3. Cell death
- •3.3.1. Apoptosis and pathogen clearance
- •3.3.2. Pyroptosis
- •3.2.3. Caspase-independent cell death
- •3.2.4. Autophagy and autophagic cell death
- •4. CONCLUSIONS
- •REFERENCES
- •Part III Cell Death in Nonmammalian Organisms
- •1. PHENOTYPE AND ASSAYS OF YEAST APOPTOSIS
- •2.1. Pheromone-induced cell death
- •2.1.1. Colony growth
- •2.1.2. Killer-induced cell death
- •3. EXTERNAL STIMULI THAT INDUCE APOPTOSIS IN YEAST
- •4. THE GENETICS OF YEAST APOPTOSIS
- •5. PROGRAMMED AND ALTRUISTIC AGING
- •SUGGESTED READINGS
- •34 Caenorhabditis elegans and Apoptosis
- •1. Overview
- •2. KILLING
- •3. SPECIFICATION
- •4. EXECUTION
- •4.1. DNA degradation
- •4.2. Mitochondrial elimination
- •4.3. Engulfment
- •5. SUMMARY
- •SUGGESTED READINGS
- •35 Apoptotic Cell Death in Drosophila
- •2. DROSOPHILA CASPASES AND PROXIMAL REGULATORS
- •6. CLOSING COMMENTS
- •SUGGESTED READINGS
- •36 Analysis of Cell Death in Zebrafish
- •1. INTRODUCTION
- •2. WHY USE ZEBRAFISH TO STUDY CELL DEATH?
- •2.2. Molecular techniques to rapidly assess gene function in embryos
- •2.2.1. Studies of gene function using microinjections into early embryos
- •2.2.2. In situ hybridization and immunohistochemistry
- •2.3. Forward genetic screening
- •2.4. Drug and small-molecule screening
- •2.5. Transgenesis
- •2.6. Targeted knockouts
- •3.1. Intrinsic apoptosis
- •3.2. Extrinsic apoptosis
- •3.3. Chk-1 suppressed apoptosis
- •3.4. Anoikis
- •3.5. Autophagy
- •3.6. Necrosis
- •4. DEVELOPMENTAL CELL DEATH IN ZEBRAFISH EMBRYOS
- •5. THE P53 PATHWAY
- •6. PERSPECTIVES AND FUTURE DIRECTIONS
- •SUGGESTED READING
172 |
RAJIV R. RATAN AND MOSES V. CHAO |
associated with cell cycle progression (e.g., E25, c-myc) are founding apoptotic neurons (Di Giovanni et al., 2003). Accordingly, a number of cell cycle inhibitors have been shown to protect neurons from cell death. One protein of particular interest is the cell cycle inhibitor, p21 waf1/cip1. Nuclear p21waf1/cip1 is classically known as a cyclin-dependent kinase inhibitor, but in its cytoplasmic form, it can negatively regulate proapoptotic proteins such as caspases and the upstream kinase, apoptosis signaling kinase-1 (ASK-1) (Coqueret, 2003). Another kinase that is inhibited by p21 that is of particular relevance to SCI and recovery is Rho kinase (Tanaka et al., 2002). The small GTPase RhoA, which has been shown to be upregulated 10-fold after SCI, activates this kinase. Indeed, RhoA inhibitors can reduce the number of TUNEL-labeled cells by 50% after SCI (Dubreuil et al., 2003). This protection is associated with decreased expression of the proneurotrophin receptor, p75. These results predict that agents that can upregulate nuclear p21 waf1/cip1 in the nucleus or cytoplasm should inhibit cell death after SCI through RhoA inhibition, cell cycle inhibition, and caspase inhibition. Agents are currently under development that enhance p21 activity. These agents could inhibit both intrinsic and extrinsic pathways to cell death.
8. CONCLUSION
Traumatic SCI triggers a host of secondary events, including ischemia, excitotoxicity, and inflammatory responses. Each of these processes can induce acute or delayed neuronal or oligodendroglial death. Cell death after SCI comes in many flavors, including classical apoptosis, classical necrosis, parthanatosis, and necroptosis. Autophagy may also contribute or mitigate death. The complexity of death signaling after SCI in neurons and oligodendrocyte underscores the complexity of interventions to reduce cell loss. Single agents that target both extrinsic and intrinsic pathways to death are attracting attention, as well as combinations that act on distinct pathways in distinct cell types. Ultimately, protection of neurons and oligodendrocytes that leads to recovery of function will be the metric by which single or combinatorial interventions can be determined to be successful.
ACKNOWLEDGMENTS
The authors would like to thank Wilfredo Milledo, Rachael Speer, and Renee Haskew-Layton for superb assistance in preparing the manuscript, including figures. R.R.R. is supported by the Richter Center for Research Excellence in Spinal Cord Injury, funded by the
SCIRP Board of the New York State Department of Health (#C019772), NIA PO1, and the Sheldon and Miriam Adelson Medical Research Foundation. M.V.C. is supported by National Institutes of Health Grants No. NS21072, AG025970, and HD23325.
REFERENCES
Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, et al. 2003. A key role for TRPM7 channels in anoxic neuronal death. Cell
115:863–77.
Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, et al. 2002. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 298:846–50.
Aminova LR, Chavez JC, Lee J, Ryu H, Kung A, et al. 2005. Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line. J Biol Chem
280:3996–4003.
Aminova LR, Siddiq A, Ratan RR. 2008. Antioxidants, HIF prolyl hydroxylase inhibitors or short interfering RNAs to BNIP3 or PUMA, can prevent prodeath effects of the transcriptional activator, HIF-1alpha, in a mouse hippocampal neuronal line.
Antioxid Redox Signal 10:1989–98.
Augoustides JG. 2008. Management of spinal cord perfusion pressure to minimize intermediate-delayed paraplegia: critical role of central venous pressure. J Thorac Cardiovasc Surg
136:796; author reply 797.
Azbill RD, Mu X, Bruce-Keller AJ, Mattson MP, Springer JE. 1997. Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury. Brain Res 765:283–90.
Bakiri Y, Hamilton NB, Karadottir R, Attwell D. 2008. Testing NMDA receptor block as a therapeutic strategy for reducing ischaemic damage to CNS white matter. Glia 56:233–40.
Beattie MS, Bresnahan JC, Komon J, Tovar CA, Van Meter M, et al. 1997. Endogenous repair after spinal cord contusion injuries in the rat. Exp Neurol 148:453–63.
Beattie MS, Harrington AW, Lee R, Kim JY, Boyce SL, et al. 2002a. ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron 36:375–86.
Beattie MS, Hermann GE, Rogers RC, Bresnahan JC. 2002b. Cell death in models of spinal cord injury. Prog Brain Res 137: 37–47.
Blight AR, Zimber MP. 2001. Acute spinal cord injury: pharmacotherapy and drug development perspectives. Curr Opin Investig Drugs 2:801–8.
Bredesen DE. 2007. Keynote lecture: toward a mechanistic taxonomy for cell death programs. Stroke 38:652–60.
Buchli AD, Rouiller E, Mueller R, Dietz V, Schwab ME. 2007. Repair of the injured spinal cord: a joint approach of basic and clinical research. Neurodegenerate dis 4(1):51–6; review.
Casha S, Yu WR, Fehlings MG. 2001. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat.
Neuroscience 103:203–18.
Cheng C, Gao S, Zhao J, Niu S, Chen M, et al. 2008. Spatiotemporal patterns of postsynaptic density (PSD)-95 expression
CELL DEATH IN SPINAL CORD INJURY – AN EVOLVING TAXONOMY WITH THERAPEUTIC PROMISE |
173 |
after rat spinal cord injury. Neuropathol Appl Neurobiol 34: 340–56.
Choi UH, Ha Y, Huang X, Park SR, Chung J, et al. 2007. Hypoxiainducible expression of vascular endothelial growth factor for the treatment of spinal cord injury in a rat model. J Neurosurg Spine 7:54–60.
Citron BA, Arnold PM, Haynes NG, Ameenuddin S, Farooque M, et al. 2008. Neuroprotective effects of caspase-3 inhibition on functional recovery and tissue sparing after acute spinal cord injury. Spine 33:2269–77.
Colak A, Karaoglan A, Barut S, Kokturk S, Akyildiz AI, Tasyurekli M. 2005. Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury. J Neurosurg Spine 2: 327–34.
Coqueret O. 2003. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13:65–70.
Cowan WM. 2001. Viktor Hamburger and Rita Levi-Montalcini: the path to the discovery of nerve growth factor. Annu Rev Neurosci 24:551–600.
Cregan SP, Dawson VL, Slack RS. 2004. Role of AIF in caspasedependent and caspase-independent cell death. Oncogene
23:2785–96.
Di Giovanni S, Knoblach SM, Brandoli C, Aden SA, Hoffman EP, Faden AI. 2003. Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. Ann Neurol 53:454–68.
Domeniconi M, Hempstead BL, Chao MV. 2007. Pro-NGF secreted by astrocytes promotes motor neuron cell death. Mol Cell Neuroscience 34:271–9.
Dong H, Fazzaro A, Xiang C, Korsmeyer SJ, Jacquin MF, McDonald JW. 2003. Enhanced oligodendrocyte survival after spinal cord injury in Bax-deficient mice and mice with delayed Wallerian degeneration. J Neurosci 23:8682–91.
Dubreuil CI, Winton MJ, McKerracher L. 2003. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J Cell Biol 162: 233–43.
Faden AI, Stoica B. 2007. Neuroprotection: challenges and opportunities. Arch Neurol 64:794–800.
Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM. 2008. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience
155:567–72.
Genovese T, Cuzzocrea S. 2008. Role of free radicals and poly(ADP-ribose)polymerase-1 in the development of spinal cord injury: new potential therapeutic targets. Curr Med Chem 15:477–87.
Germain M, Milburn J, Duronio V. 2008. MCL-1 inhibits BAX in the absence of MCL-1/BAX Interaction. J Biol Chem 283: 6384–92.
Gilman CP, Mattson MP. 2002. Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility? Neuromolecular Med 2:197–214.
Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ. 1987. Expression of Bcl-2 and Bcl-2-Ig fusion
transcripts in normal and neoplastic cells. J Clin Invest 80: 1512–5.
Gupta A, Taly AB, Srivastava A, Murali T. 2009. Non-traumatic spinal cord lesions: epidemiology, complications, neurological and functional outcome of rehabilitation. Spinal Cord
47:307–11.
Gupta A, Taly AB, Srivastava A, Vishal S, Murali T. 2008. Traumatic vs non-traumatic spinal cord lesions: comparison of neurological and functional outcome after in-patient rehabilitation. Spinal Cord 46:482–7.
Haas LF. 1999. Papyrus of Ebers and Smith. J Neurol Neurosurg Psychiatry 67:578.
Haghighi SS, Hall ED, Geng XZ, Oro JJ, Johnson GC. 1993. Therapeutic value of 21-aminosteroid U74389F in acute spinal cord injury. Neurol Res 15:321–6.
Hall ED. 1993a. The effects of glucocorticoid and nonglucocorticoid steroids on acute neuronal degeneration. Adv Neurol
59:241–8.
Hall ED. 1993b. Neuroprotective actions of glucocorticoid and nonglucocorticoid steroids in acute neuronal injury. Cell Mol Neurobiol 13:415–32.
Hamacher-Brady A, Brady NR, Gottlieb RA. 2006a. Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes. J Biol Chem 281:29776–87.
Hamacher-Brady A, Brady NR, Gottlieb RA. 2006b. The interplay between pro-death and pro-survival signaling pathways in myocardial ischemia/reperfusion injury: apoptosis meets autophagy. Cardiovasc Drugs Ther 20:445–62.
Hamacher-Brady A, Brady NR, Gottlieb RA, Gustafsson AB. 2006c. Autophagy as a protective response to Bnip3-mediated apoptotic signaling in the heart. Autophagy 2:307–9.
Hamburger V. 1992. History of the discovery of neuronal death in embryos. J Neurobiol 23:1116–23.
Harrington AW, Kim JY, Yoon SO. 2002. Activation of Rac GTPase by p75 is necessary for c-jun N-terminal kinase-mediated apoptosis. J Neurosci 22:156–66.
Harrington AW, Leiner B, Blechschmitt C, Arevalo JC, Lee R, et al. 2004. Secreted proNGF is a pathophysiological deathinducing ligand after adult CNS injury. Proc Natl Acad Sci U S A 101:6226–30.
Hempstead BL. 2006. Dissecting the diverse actions of proand mature neurotrophins. Curr Alzheimer Res 3:19–24.
Jansen P, Giehl K, Nyengaard JR, Teng K, Lioubinski O, et al. 2007. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat Neurosci
10:1449–57.
Kanno H, Ozawa H, Sekiguchi A, Itoi E. 2009. Spinal cord injury induces upregulation of Beclin 1 and promotes autophagic cell death. Neurobiol Dis 33:143–8.
Keane RW, Kraydieh S, Lotocki G, Bethea JR, Krajewski S, et al. 2001. Apoptotic and anti-apoptotic mechanisms following spinal cord injury. J Neuropathol Exp Neurol 60: 422–9.
Kerr JF. 2002. History of the events leading to the formulation of the apoptosis concept. Toxicology 181–2:471–4.
Kieran D, Woods I, Villunger A, Strasser A, Prehn JH. 2007. Deletion of the BH3-only protein puma protects motoneurons
174 |
RAJIV R. RATAN AND MOSES V. CHAO |
from ER stress-induced apoptosis and delays motoneuron loss in ALS mice. Proc Natl Acad Sci U S A 104:20606–11.
King VR, Averill SA, Hewazy D, Priestley JV, Torup L, MichaelTitus AT. 2007. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 26:90–100.
Knoblach SM, Huang X, VanGelderen J, Calva-Cerqueira D, Faden AI. 2005. Selective caspase activation may contribute to neurological dysfunction after experimental spinal cord trauma. J Neurosci Res 80:369–80.
Lau A, Arundine M, Sun HS, Jones M, Tymianski M. 2006. Inhibition of caspase-mediated apoptosis by peroxynitrite in traumatic brain injury. J Neurosci 26:11540–53.
Lee R, Kermani P, Teng KK, Hempstead BL. 2001. Regulation of cell survival by secreted proneurotrophins. Science 294: 1945–8.
Li GL, Farooque M, Olsson Y. 2000. Changes of Fas and Fas ligand immunoreactivity after compression trauma to rat spinal cord. Acta Neuropathol 100:75–81.
Li QM, Tep C, Yune TY, Zhou XZ, Uchida T, et al. 2007. Opposite regulation of oligodendrocyte apoptosis by JNK3 and Pin1 after spinal cord injury. J Neurosci 27:8395–404.
Liu XZ, Xu XM, Hu R, Du C, Zhang SX, et al. 1997. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci
17:5395–406.
Lucas JH, Wheeler DG, Guan Z, Suntres Z, Stokes BT. 2002. Effect of glutathione augmentation on lipid peroxidation after spinal cord injury. J Neurotrauma 19:763–75.
Maciel EN, Vercesi AE, Castilho RF. 2001. Oxidative stress in Ca(2+)-induced membrane permeability transition in brain mitochondria. J Neurochem 79:1237–45.
Massa SM, Xie Y, Yang T, Harrington AW, Kim ML, et al. 2006. Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J Neurosci 26:5288–300.
Matsushita K, Wu Y, Qiu J, Lang-Lazdunski L, Hirt L, et al. 2000. Fas receptor and neuronal cell death after spinal cord ischemia. J Neurosci 20:6879–87.
Moubarak RS, Yuste VJ, Artus C, Bouharrour A, Greer PA, et al. 2007. Sequential activation of poly(ADP-ribose) polymerase 1, calpains, and Bax is essential in apoptosis-inducing factormediated programmed necrosis. Mol Cell Biol 27:4844–62.
Okutan O, Solaroglu I, Beskonakli E, Taskin Y. 2007. Recombinant human erythropoietin decreases myeloperoxidase and caspase-3 activity and improves early functional results after spinal cord injury in rats. J Clin Neurosci 14:364–8.
Pinzon A, Marcillo A, Quintana A, Stamler S, Bunge MB, et al. 2008. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res
1243:146–51.
Ratan RR, Siddiq A, Smirnova N, Karpisheva K, Haskew-Layton R, et al. 2007. Harnessing hypoxic adaptation to prevent, treat, and repair stroke. J Mol Med 85:1331–8.
Ravikumar R, McEwen ML, Springer JE. 2007. Post-treatment with the cyclosporin derivative, NIM811, reduced indices of cell death and increased the volume of spared tissue in the
acute period following spinal cord contusion. J Neurotrauma
24:1618–30.
Ray SK, Matzelle DD, Wilford GG, Hogan EL, Banik NL. 2001a. Cell death in spinal cord injury (SCI) requires de novo protein synthesis. Calpain inhibitor E-64-d provides neuroprotection in SCI lesion and penumbra. Ann N Y Acad Sci 939:436–49.
Ray SK, Matzelle DD, Wilford GG, Hogan EL, Banik NL. 2001b. Inhibition of calpain-mediated apoptosis by E-64 d-reduced immediate early gene (IEG) expression and reactive astrogliosis in the lesion and penumbra following spinal cord injury in rats. Brain Res 916:115–26.
Reed JC, Tsujimoto Y, Alpers JD, Croce CM, Nowell PC. 1987. Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science 236:1295–9.
Ruan B, Pong K, Jow F, Bowlby M, Crozier RA, et al. 2008. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci U S A 105:33–8.
Semenza GL. 2008a. Mitochondrial autophagy: life and breath of the cell. Autophagy 4:534–6.
Semenza GL. 2008b. O2 sensing: only skin deep? Cell 133:206–8. Shi E, Jiang X, Kazui T, Washiyama N, Yamashita K, et al.
2007. Controlled low-pressure perfusion at the beginning of reperfusion attenuates neurologic injury after spinal cord ischemia. J Thorac Cardiovasc Surg 133:942–8.
Siegel RM, Muppidi J, Roberts M, Porter M, Wu Z. 2003. Death receptor signaling and autoimmunity. Immunol Res 27: 499–512.
Soengas MS, Lowe SW. 2003. Apoptosis and melanoma chemoresistance. Oncogene 22:3138–51.
Soriano FX, Martel MA, Papadia S, Vaslin A, Baxter P, et al. 2008. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci
28:10696–710.
Springer JE, Azbill RD, Kennedy SE, George J, Geddes JW. 1997a. Rapid calpain I activation and cytoskeletal protein degradation following traumatic spinal cord injury: attenuation with riluzole pretreatment. J Neurochem 69:1592–600.
Springer JE, Azbill RD, Mark RJ, Begley JG, Waeg G, Mattson MP. 1997b. 4-hydroxynonenal, a lipid peroxidation product, rapidly accumulates following traumatic spinal cord injury and inhibits glutamate uptake. J Neurochem 68:2469–76.
Sribnick EA, Matzelle DD, Banik NL, Ray SK. 2007. Direct evidence for calpain involvement in apoptotic death of neurons in spinal cord injury in rats and neuroprotection with calpain inhibitor. Neurochem Res 32:2210–6.
Steckley D, Karajgikar M, Dale LB, Fuerth B, Swan P, et al. 2007. Puma is a dominant regulator of oxidative stress induced Bax activation and neuronal apoptosis. J Neurosci 27:12989–99.
Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, et al. 2004. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 24:2182–90.
Sugawara T, Lewen A, Gasche Y, Yu F, Chan PH. 2002. Overexpression of SOD1 protects vulnerable motor neurons after
CELL DEATH IN SPINAL CORD INJURY – AN EVOLVING TAXONOMY WITH THERAPEUTIC PROMISE |
175 |
spinal cord injury by attenuating mitochondrial cytochrome c release. FASEB J 16:1997–9.
Sun J, Druhan LJ, Zweier JL. 2008. Dose dependent effects of reactive oxygen and nitrogen species on the function of neuronal nitric oxide synthase. Arch Biochem Biophys 471:126–33.
Taccola G, Margaryan G, Mladinic M, Nistri A. 2008. Kainate and metabolic perturbation mimicking spinal injury differentially contribute to early damage of locomotor networks in the in vitro neonatal rat spinal cord. Neuroscience 155:538–55.
Takagi T, Takayasu M, Mizuno M, Yoshimoto M, Yoshida J. 2003. Caspase activation in neuronal and glial apoptosis following spinal cord injury in mice. Neurol Med Chir (Tokyo) 43:20–9; discussion 9–30.
Tanaka H, Yamashita T, Asada M, Mizutani S, Yoshikawa H, Tohyama M. 2002. Cytoplasmic p21(Cip1/WAF1) regulates neurite remodeling by inhibiting Rho-kinase activity. J Cell Biol 158:321–9.
Troy CM, Salvesen GS. 2002. Caspases on the brain. J Neurosci Res 69:145–50.
Uo T, Kinoshita Y, Morrison RS. 2007. Apoptotic actions of p53 require transcriptional activation of PUMA and do not involve a direct mitochondrial/cytoplasmic site of action in postnatal cortical neurons. J Neurosci 27:12198–210.
Xu J, Kim GM, Chen S, Yan P, Ahmed SH, et al. 2001. iNOS and nitrotyrosine expression after spinal cord injury. J Neurotrauma 18:523–32.
Yakovlev AG, Faden AI. 2001. Caspase-dependent apoptotic pathways in CNS injury. Mol Neurobiol 24:131–44.
Yin KJ, Kim GM, Lee JM, He YY, Xu J, Hsu CY. 2005. JNK activation contributes to DP5 induction and apoptosis following traumatic spinal cord injury. Neurobiol Dis 20: 881–9.
Yu F, Sugawara T, Nishi T, Liu J, Chan PH. 2006. Overexpression of SOD1 in transgenic rats attenuates nuclear translocation of endonuclease G and apoptosis after spinal cord injury. J Neurotrauma 23:595–603.
Yu LY, Korhonen L, Martinez R, Jokitalo E, Chen Y, et al. 2003. Regulation of sympathetic neuron and neuroblastoma cell death by XIAP and its association with proteasomes in neural cells. Mol Cell Neurosci 22:308– 18.
Yune TY, Lee JY, Jung GY, Kim SJ, Jiang MH, et al. 2007. Minocycline alleviates death of oligodendrocytes by inhibiting pronerve growth factor production in microglia after spinal cord injury. J Neurosci 27:7751–61.
Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, et al. 2008. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 283: 10892–903.
Zurita M, Vaquero J, Zurita I. 2001. Presence and significance of CD-95 (Fas/APO1) expression after spinal cord injury.
J Neurosurg 94:257–64.